BridgeBio Oncology Therapeutics, Inc. ('BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ant ...
Immuneering will present an analysis of circulating tumor DNA (ctDNA) from ≥64 patients with RAS-mutant solid tumors treated with atebimetinib, showing that acquired MAPK pathway alterations are ...
In addition to their weight loss benefits, GLP-1 RAs also act on neural circuits involved in appetite, impulse control, and ...
RIT biomedical engineering researchers identify a protein that can reduce fibrosis and slow disease progression.
The skin is far more than a simple physical barrier. These two researches address a fundamental question in immunology: How does a localized skin ...
On March 4, 2026, Verastem posted an updated corporate presentation outlining its strategy around AVMAPKI FAKZYNJA co-pack for KRAS mutant recurrent low-grade serous ovarian cancer and its broader RAS ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
Dr McIntyre and colleagues share new insight on how GLP-1 receptor agonists may protect against lithium-induced kidney damage in patients treated for bipolar disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results